找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Data Monitoring in Clinical Trials; A Case Studies Appro David L. DeMets,Curt D. Furberg,Lawrence M. Friedm Book 2006 Springer-Verlag New Y

[復制鏈接]
樓主: hexagon
21#
發(fā)表于 2025-3-25 05:57:42 | 只看該作者
22#
發(fā)表于 2025-3-25 09:06:06 | 只看該作者
Richard Lai,Ajin Jirachiefpattanaarction. The primary outcome was total mortality. The trial ended nine months ahead of schedule because of clear benefit from propranolol. The independent monitoring committee considered several newly developed statistical approaches in recommending early stopping, as well as other factors, includin
23#
發(fā)表于 2025-3-25 12:18:46 | 只看該作者
24#
發(fā)表于 2025-3-25 16:25:40 | 只看該作者
25#
發(fā)表于 2025-3-25 23:57:25 | 只看該作者
26#
發(fā)表于 2025-3-26 00:20:23 | 只看該作者
https://doi.org/10.1007/978-3-030-50405-2200 mg daily) with clotrimazole lozenges (10mg, five times daily) for prevention of invasive fungal infections in patients with advanced HIV disease. At the fourth DSMB review of the study in November 1992, the patients on fluconazole had a significantly lower risk of invasive, serious and superfici
27#
發(fā)表于 2025-3-26 07:45:48 | 只看該作者
28#
發(fā)表于 2025-3-26 11:25:38 | 只看該作者
Communication Rights and Social Justice91 patients with New York Heart Class II–IV heart failure and LVEF ≤0.40. The two primary objectives were to determine the effect of metoprolol CR/XL on all-cause mortality and on the combined endpoint of all-cause mortality or all-cause hospitalizations (time to first event). There was a two-week p
29#
發(fā)表于 2025-3-26 12:51:07 | 只看該作者
Media Justice and Communication Rights of daily spironolactone to standard therapy would reduce the risk of all-cause mortality in patients with severe heart failure as a result of systolic left ventricular dysfunction. The Data Safety Monitoring Board (DSMB) for RALES reviewed data on safety and efficacy throughout the trial using pre-
30#
發(fā)表于 2025-3-26 18:20:28 | 只看該作者
The Essentials of Nursing Management Seriesin the data, but also to avoid the loss of important treatment information concerning secondary outcomes, key subgroups, and patient safety data. For the Heart Outcomes Prevention Evaluation (HOPE) and Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trials, their Data and
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-31 04:20
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
永昌县| 宁海县| 修文县| 嵊州市| 鲁山县| 沾化县| 柳河县| 微山县| 枣阳市| 吉水县| 巴彦淖尔市| 和静县| 荃湾区| 儋州市| 行唐县| 武隆县| 陕西省| 远安县| 平塘县| 吉木萨尔县| 廉江市| 仁布县| 开化县| 加查县| 淮安市| 黄陵县| 竹山县| 柳州市| 民丰县| 张家港市| 临城县| 漳平市| 鹿泉市| 旌德县| 青海省| 嵊泗县| 阿荣旗| 星子县| 安吉县| 惠来县| 洪江市|